Drugs / Harmine
Harmine
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05780216 | Feb → Aug 2023 | — | Milan Scheidegger | Completed | No outcome recorded |
| Phase 0 | NCT04716335 | Dec 2020 → Jul 2021 | CGF1 | Psychiatric University Hospital, Zurich | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06252506 | Jan 2024 → Feb 2025 | — | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 1 | NCT05829603 | May → Sep 2023 | — | Reconnect Labs | Completed | No outcome recorded |
| Phase 1 | NCT05526430 | Sep 2022 → Jun 2023 | diabetes mellitus | James Murrough | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | harmine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06252506 ↗ |
| Known as | HARMINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL269538 ↗ |
| Known as | HARMINE HYDROCHLORIDE HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL269538 ↗ |
| Action | Inhibit | “combined with the monoamine oxidase inhibitor harmine (DMT-harmine)” PMID 39340164 ↗ Sep 2024 |
| Modality | Small molecule | — CHEMBL269538 ↗ |
| Route | Oral | “Each study subject will receive a single oral dose of harmine in this single ascending dose design.” NCT05526430 ↗ |